Background: The impact of clinical trials on medical practice remains controversial, in part because of weak study designs and nonrepresentative study samples.
Objective: To assess changes in trends in medication use in the setting of acute myocardial infarction (AMI) before and after publication of two large clinical trials: the Second International Study of Infarct Survival (ISIS-2) trial that supported the use of aspirin after AMI and the Multicenter Diltiazem Postinfarction Trial that reported no overall benefit from the use of calcium antagonists after AMI.
Methods: Study patients consisted of 2114 patients hospitalized with AMI in 16 hospitals in metropolitan Worcester, Mass, during 1986 Mass, during ,1988 Mass, during , and 1990 . Data were obtained from medical records. We used multivariable logistic regression models to examine the rate of change in the use of selected medications before and after trial publication, controlling for medical history, characteristics and complications of AMI, medications taken, and procedures performed during hospitalization. The dependent variable was receipt of the specific medication under investigation.
Results: Before publication of ISIS-2, 26% of patients with AMI received aspirin while hospitalized compared with 66% after its publication. However, in-hospital aspirin use began to rise before ISIS-2 with an immediate increase in the level of use occurring after trial publication but with no significant change in the rate of increase. Before publication of the Multicenter Diltiazem Postinfarction Trial, 57% of patients with AMI were new recipients of calcium antagonists compared with 51% after trial publication. The decrease in calcium antagonist use began after trial publication (odds ratio, 0.79 per 6-month period; 95% confidence interval, 0.71 to 0.88).
Conclusions: The published results of large trials of cardiovascular therapies have had variable impact on medication use. Efforts to assess the effects of publication of new scientific information on medical care need to consider prior trends in treatment The randomized controlled trial (RCT) represents the principal means for evalu¬ ating the efficacy of therapeutic agents.
While several studies have attempted to evaluate the direct impact of RCTs on clini¬ cal practice,1"3 divergent results have been observed. One review4 of the published lit¬ erature found that only two of 25 studies reviewed were able to demonstrate a de¬ tectable change in clinical practice based on publication of the results of an RCT. 5, 6 A recent study found the publica¬ tion of large RCTs on the treatment of acute myocardial infarction (AMI) to be associated with measurable changes in clinical practice.7 However, this study was performed within the context of a large RCT (the Survival and Ventricular En¬ largement [SAVE] Trial8). The study sub¬ jects were a highly select group represent¬ ing less than 10% of patients with AMI who met eligibility requirements and had sur¬ vived the acute hospitalization for at least 72 hours,9 thereby raising questions con¬ cerning generalizability to broader com¬ munity settings. In addition, the possibil¬ ity exists that the observed changes in practice patterns may have begun before the publication of the RCT.
A variety of nonscientific factors can also affect prescribing practices over time. These include pharmaceutical company METHODS We examined the use of aspirin and calcium antagonists among patients hospitalized with validated AMI. The study population was drawn from the Worcester Heart Attack Study, a population-based investigation examining changes over time in the incidence, case-fatality rates, and treat¬ ment patterns for AMI among residents from a defined popu¬ lation setting.18"23 The study population, identified by a re¬ view of medical records, included all patients hospitalized with a primary or secondary discharge diagnosis of AMI in 16 Worcester, Mass, Standard Metropolitan Statistical Area hospitals during the calendar years 1986, 1988, and 1990. The patients' medical records were individually re¬ viewed and validated for the presence of AMI. The criteria used for the diagnosis of AMI in our study have been de¬ scribed previously18 20 and include a clinical history of pro¬ longed chest pain not relieved by rest or use of sublingual nitrates, elevation of the level of serum creatine kinase and its isoenzyme subfraction or of the level of lactate dehydrogenase, and serial electrocardiographic tracings ob¬ tained during hospitalization showing ST-segment changes or Q waves or both typical of AMI. At least two criteria were needed to be satisfied for inclusion in the study. The data obtained from the medical record included patient demo¬ graphic characteristics, medical history, characteristics of the AMI (eg, AMI order, extent, and location), medications taken before and during hospitalization, complications of AMI occurring during the acute hospital admission, spe¬ cialized procedures performed during hospitalization, and date of hospitalization. We were not able to obtain data on the prescribing physician. The data on in-hospital medication use were obtained from nurses' notes to ensure that patients actually received the medication in question. Only class-specific data on medication use were obtained for calcium antagonists; we distinguished between newly initiated and continuation of ongoing therapy. DATA ANALYSIS Differences in selected continuous or categorical data were assessed by Student's í tests and the x2 tests of statistical significance, respectively. The Cochran-Mantel-Haentzel x2 test was used to assess the significance of any observed trends in drug use or baseline characteristics over the period un¬ der study; all P values were two tailed. The impact of spe¬ cific published RCTs on medication use was assessed us¬ ing multivariable logistic regression models to test the association between medication use and date of hospital admission; the dependent variable examined in these analy¬ ses was receipt of the specific medication under investiga¬ tion. Initial analyses were similar to those performed in a recent analysis8 and did not account for preexisting time trends in medication use; the date of hospital admission was characterized as a dichotomous variable occurring ei¬ ther before or after publication of the relevant RCT. A sec¬ ond set of analyses accounted for any changes in practice patterns occurring before publication of the RCT. By in¬ corporating variables that capture changes in medication use before and after publication of RCT results, these mod¬ els enabled us to examine both the immediate trial effect and monthly changes following the publication of trial results compared with pretrial publication. Similar types of modeling approaches have been previously used to assess the impact of policy changes on drug use, using linear regression models.2425 To adjust for potential confounders at the individual patient level, these linear modeling techniques were modified to multivariable logistic regression models.2" These models included a linear term for hospitalization month (representing the monthly rate of change in the log odds ratio [OR] for receipt of the medication before trial publication), a dichotomous term for admission before or after publica¬ tion of the RCT (representing the level of change occur¬ ring immediately after publication of the RCT), as well as an interaction term representing the change in slope occurring after trial publication. The immediate trial effect compares drug use in the month after trial publi¬ cation with that in the month preceding publication, incorporating both slope and level change variables. The month in which the trial was published was split on the day of publication into prepublication vs postpublication periods. Variables that changed significantly over the period under investigation or that were associated with medication use in univariate analyses were included in these models to give as complete control for confound¬ ing as possible. Models examining in-hospital aspirin use included the following: patient age, gender, and type of insurance coverage; hospital size (based on the num¬ ber of patients with AMI treated per year); history of angina, congestive heart failure, or diabetes; complica¬ tions of AMI (recurrent angina, cardiac arrest, conges¬ tive heart failure, or pulmonary edema, or ventricular tachycardia); procedures performed during hospitaliza¬ tion (percutaneous transluminal coronary angioplasty and coronary artery bypass graft); and receipt of thrombolytic therapy. The models examining the impact of RCTs on calcium antagonist use additionally included: history of AMI; characteristics of AMI (infarct size as determined by peak creatine kinase findings, Q wave or non-Q wave, and inferior and/or posterior vs anterior AMI), and complications of AMI (cardiogenic shock, extension of AMI, ventricular fibrillation, and thirddegree heart block). We controlled for within-hospital correlation in the logistic regression models using previ¬ ously described methods. 27"29 Recognizing that publicity was generated during the course of these trials and that results were reported at a large conference several months before their publication in a peerreviewed journal,30 logistic regression models were re¬ peated using the conference reporting date as the cut¬ off time.
To determine the relative influence of RCTs in a primarily community setting vs a primarily academic setting, we compared patterns of drug use over time for patients in the community-based Worcester Heart Attack Study with patients enrolled in a large RCT promotions and introduction of new products to the mar¬ ketplace10J1; government regulations and reimburse¬ ment restrictions1213; media reports14; and formal and in¬ formal peer influence through specialty organizations and opinion leaders.13 Even though these factors may be in¬ directly affected by published RCTs, they are likely to rep¬ resent stronger influences on prescribing practices in com¬ munity settings than publication of RCTs alone. 16 The failure to control for preexisting trends in prescribing caused by such nonscientific factors has been shown to produce spurious and often inflated estimates of the ef¬ fects of educational interventions on prescribing pat¬ terns.1617
The purpose of our study is to assess the impact of large published RCTs of cardiovascular medications on clinical practice from a community-wide perspective and to examine whether controlling for prepublication trends in medication use affects the conclusions drawn.
RESULTS
A total of 2114 patients in the Worcester area had a vali¬ dated AMI during 1986,1988, and 1990. The median age of the patient population was 68 years; 61% were men. The patient characteristics and use of drugs and proce¬ dures were generally stable over time (Table 1 ) , except for an increase in the use of thrombolytic agents.
ASPIRIN USE DURING HOSPITALIZATION
Forty-four percent of all study patients received aspirin during their hospitalization for AMI. The percentage of patients receiving aspirin increased from 19% in the first half of 1986 to 75% during the last half of 1990. Before the publication of ISIS-2, 26% of patients with AMI re¬ ceived aspirin compared with 66% subsequent to its pub- lication. Using multivariable logistic regression models that did not account for time trends occurring before trial publication, patients hospitalized after publication of ISIS-2 were significantly more likely to be treated with aspirin than those hospitalized before its publication (ad¬ justed OR, 6.6; 95% confidence interval [CI], 5.3 to 8.2).
However, the trend toward increased use of aspirin after infarction began before publication of ISIS-2. During the period before publication of this trial, aspirin use in¬ creased from 20% (first quarter, 1986) to 37% (third quar¬ ter, 1988) (P<.001; unadjusted OR, 1.26 per 6-month period; 95% CI, 1.18 to 1.36) ( Figure I ).
When multivariable regression models were repeated controlling for time trends in aspirin use before trial publication, the OR for receipt of aspirin increased significantly before trial publication (ad¬ justed OR, 1.24 per 6-month period; 95% CI, 1.15 to 1.34) (Table 31 ). After publication of ISIS-2 there was an immediate increase in aspirin use (adjusted OR, 1.77; 95% CI, 1.19 to 2.65). The posttrial publication trend continued to increase at the same rate as during the prepublication period. Using multivariable logistic regression models that accounted for within hospital correlation of medication use,27"2" similar results were obtained.
When these regression models were repeated ( nists, decreasing to 24% during the latter half of 1990 ( Figure 2 ).
Using multivariable logistic regression models that did not account for time trends occurring before publica¬ tion, patients hospitalized after trial publication were sig¬ nificantly less likely to be newly receiving calcium antago¬ nists than those hospitalized before trial publication (adjusted OR, 0.59; 95% CI, 0.49 to 0.71). When these regression analyses were repeated controlling for changes in calcium antagonist use over time, no significant time trend in the new initiation of calcium antagonists was ob¬ served before trial publication (adjusted OR, 1.04 per 6-month period; 95% CI, 0.97 to 1.11). Although no immediate trial effect was observed, a significant trend toward decreased use was observed after publication (adjusted OR, 0.79; 95% CI, 0.71 to 0.88) ( Figure 3 ). When using multivariable logistic regression models accounting for within-hospital correlation of medication use,27"29 the find¬ ings were similar to the reported results.
When models were repeated using the date of con¬ ference reporting as the threshold instead of trial publi¬ cation date, similar results were obtained. The adjusted OR for new receipt of calcium channel blockers before the conference reporting date was 1.07 per 6-month pe-riod (95% CI, 0.96 to 1.19) . After the time of the con¬ ference report, this adjusted OR decreased to 0.81 per 6-month period (95% CI, 0.76 to 0.87). An immediate decrease in new calcium channel blocker use occurred during the month after the results of this trial were reported (adjusted OR, 0.29; 95% CI, 0.10 to 0.61).
Because subgroup analyses from the MDPT sug¬ gested that patients with non-Q-wave AMI might selec¬ tively benefit from the administration of calcium antago¬ nists in the postinfarction period, tests for time trends were repeated while stratifying patients into those with Q-wave vs those with non-Q-wave AMI. Among pa¬ tients with Q-wave AMIs, no time trends in the new re¬ ceipt of calcium antagonists were detected before trial pub¬ lication (46% to 48%), whereas use of calcium antagonists decreased substantially after trial publication (48% to 15%, P=.001). Among patients with non-Q-wave AMIs, no sig¬ nificant change in use occurred either before or after trial publication (before publication, 35% to 43%, P=.06; af¬ ter publication, 43% to 36%, P=.08 ).
DIFFERENCES IN DRUG USE BETWEEN THE COMMUNITY SETTING AND WITHIN THE SAVE TRIAL
Patterns of drug use observed in the present community setting were compared with those of patients included in the SAVE Trial8 during similar time periods before pub¬ lication or conference reporting of trial results (Decem¬ ber 1986 for the community setting compared with Janu¬ ary 1987 for SAVE patients), recognizing that patients included in the SAVE Trial were younger and healthier than those in the community setting. In-hospital aspirin use was lower in the community setting (18% com¬ pared with 39% in the SAVE Trial), whereas baseline cal¬ cium antagonist use was comparable in both settings (55% vs 57%). We were able to compare the rates of change in medication use in the community setting with that ob¬ served within the SAVE Trial from this period to Janu¬ ary 1990. Aspirin use increased significantly more rap¬ idly in the Worcester community sample than within the SAVE Trial (222% vs 85%). The decline in the use of cal¬ cium antagonists was lower in the community setting (2%) during this period than within the SAVE Trial (42%) de¬ spite similar baseline levels of use. At the last point in time for which the two study populations could be com¬ pared (January 1990), the use of aspirin was lower in the Worcester community setting (57%) than within the SAVE Trial (72%). The use of calcium antagonists was higher in the community setting than within the SAVE Trial (55% vs33%).
The RCT has become the gold standard for evaluating the efficacy of therapeutic practices. However, such tri¬ als require large numbers of patients, involve a long du¬ ration of follow-up, and are very costly and logistically difficult to conduct.3 The rigid inclusion and exclusion criteria imposed in these trials raise questions concern¬ ing the generalizability of the findings to patients treated in community settings. Given these concerns, it is im- portant to assess the impact of published RCTs on com¬ munity medical practice, rather than only within the con¬ structs of more specialized academic medical centers. Our results were sensitive to the analytic approach used. When using a simple before and after quasiexperimental design similar to methods used in a recent study,8 we observed changes in both of the medication categories investigated that suggested a marked effect of RCTs on community practice. However, when trends be¬ fore publication of the RCT were taken into account in subsequent analyses, a more complex picture emerged. We found publication of ISIS-2 to have a limited impact on in-hospital aspirin use, with only an immediate (ie, 1 month) effect detectable. Reporting of ISIS-2 trial re¬ sults several months before its publication in a peerreviewed journal appeared to have a greater discernible impact on aspirin use than did its actual publication and may have started the upward trend that was observed. Although a statistically significant decline in the rate of use of calcium channel blockers was observed after pub¬ lication of the RCT, the magnitude of this change was small.
The main strength of our study is its inclusion of a large number of community patients with validated AMI. The demographic and socioeconomic characteristics of residents in the Worcester metropolitan area are similar to those of the continental United States. The main limitations of our study include the relatively short duration of follow-up time after trial publication, lack of data for the interim years 1987 and 1989 to more systematically examine changes over time in medica-tion patterns, and lack of information on the prescrib¬ ing physicians.
Differences between the results of the present study and those found in the SAVE Trial could reflect real dif¬ ferences in patterns of drug use between the commu¬ nity and academic settings. Alternatively, they may stem from different analytic methods applied in the two stud¬ ies as well as from differences in measured or unmea¬ sured patient characteristics. Previous studies have dem¬ onstrated that research designs failing to control for preintervention trends have produced inflated esti¬ mates of the effects of educational and regulatory inter¬ ventions on prescribing practice.1718 Similarly, the fail¬ ure to consider trends occurring before the publication of RCTs may have led to an overestimation of the influ¬ ence of an individual RCT on clinical practice. For ex¬ ample, results published by the SAVE Trial investiga¬ tors showed that aspirin use after AMI increased from 39% to nearly 60% before publication of ISIS-2 (fromJanu¬ ary 1987 to the first half of 1988), though this increase was not accounted for in subsequent analyses.
Several difficulties arise in trying to determine the impact of publication of an individual RCT on clinical practice. While we focused on the impact of very large RCTs, there were, in fact, numerous ongoing trials en¬ dorsing changes in clinical practice, making it difficult to discern the influence of a single study on physicians' practice patterns. Failure to observe a large impact of the publication of the ISIS-2 trial on aspirin use may have been influenced by the prior accumulation of evidence (publication of other trials or meta-analyses) concern-ing the efficacy of aspirin in the secondary prevention of cardiovascular-related events."4Î More importantly, some of the increase in aspirin use seen before publica¬ tion of the ISIS-2 could be directly related to the trial it¬ self. Since this trial was conducted over several years be¬ fore publication of its results, publicity generated during its conduct could have affected prescribing patterns. Our study demonstrates the impact that the reporting of re¬ sults of this trial had on clinical practice.
The differences in patterns of drug use observed be¬ tween the community setting of our study and within the context of the SAVE Trial may partially be explained by the strict inclusion and exclusion criteria applied to pa¬ tients within the SAVE Trial. Subjects in an RCT are typi¬ cally younger and with fewer comorbidities than those studied in the community setting, and they are likely to have fewer contraindications to medication therapy.44 This may account for the increased baseline rate of aspirin use observed within the SAVE Trial. Additionally, patients in the SAVE Trial had decreased ejection fractions, mak¬ ing them less likely to receive calcium antagonists. Dif¬ ferences in the characteristics and practice patterns of the physician populations in these two groups may also in¬ fluence the prescribing patterns observed. Certain phy¬ sician characteristics (type of practice, board certifica¬ tion, specialization) are likely to influence their knowledge of RCTs and willingness to adopt or abandon clinical prac¬ tices.4546 More physicians involved in the SAVE Trial may have been specialists, board certified, or engaged in group practice, factors that would presumably increase their fa¬ miliarity with and rate of adoption of new clinical prac¬ tices. Furthermore, their involvement in a large RCT might have exposed them to more communication channels than community-based physicians.
When one considers an RCT as an initial step in a complex sequence of events leading to physician aware¬ ness, acceptance of trial results, trial of new clinical prac¬ tices, and adoption of new clinical behaviors,47 it may take many years for the full impact of an RCT on clinical prac¬ tice to be realized. In addition, behavior change may de¬ pend on acceptance of the innovation by local opinion leaders. 48 Although we were able to follow practice pat¬ terns for up to 2 years after the publication of trial re¬ sults, a longer follow-up period would have been desir¬ able. A recent study49 found a time lag of at least 3 years between the onset of a change in practice and the attain¬ ment of a steady state in practice patterns.
While the publication of the results of an RCT may herald changes in clinical practice patterns, changes in practice may precede the demonstration of efficacy by publication of a clinical trial. Our study shows that as¬ pirin use during hospitalization for AMI began to in¬ crease after reporting of the ISIS-2 trial before its publi¬ cation, with no significant change in the rate of increase occurring after publication. On the other hand, the trend toward a decreasing use of calcium antagonists was tem¬ porally associated, albeit small, with the publication of the MDPT and SPRINT trials.
That physicians do not always rely on the results of clinical trials to guide their practice is more understand¬ able when one considers that clinical practice has evolved over the years largely without the benefit of RCTs. One study estimated that RCTs have been applied to only 10% to 20% of medical practices.50 A study51 tracing the in¬ troduction of innovative practices in surgery and anes¬ thesia found that only one third of 107 innovations were based on results obtained from clinical trials. In light of the clear but limited impact of publica¬ tion of the results of an individual RCT on clinical prac¬ tice in the community and the tremendous investments required for the successful conduct and completion of a clinical trial, more emphasis should be placed on assess¬ ing active dissemination of the results of RCTs to com¬ munity-based physicians and on identifying and over¬ coming barriers to the acceptance of new practices that are shown to be efficacious.
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